The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
List view / Grid view
Filter the results
Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
8 July 2016 | By Victoria White, Digital Content Producer
Eisai has expressed concern that patients in England and Wales will have to wait three years to access Lenvatinib due to a ‘black hole’ in the CDF process...
12 May 2016 | By Victoria White, Digital Content Producer
The FDA has granted Orphan Drug Designation for selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC)...
2 March 2016 | By Victoria White, Digital Content Producer
The trial will evaluate sulfatinib in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer....